96 Tests PN: B113530

Components:

45x Ab-conjugated beads (S4P10 - Human EGFR Ab-bead). PN: B113530A. One vial containing 100 µL of anti-human EGFR conjugated to AimPlex Bead S4P10.

25x Biotin-detection Ab (Human EGFR Biotin-dAb). PN: B113530B. One vial containing    100 µL of biotinylated anti- Human EGFR.

Lyophilized Standard Mix - Human EGFR. PN: B113530S. One vial containing lyophilized EGFR.

Application: Optimal antibody pair and antigen standard for assaying human Human EGFR/ErbB1. To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 50 pg/mL

  • Quantitation range:

  • LLOQ: < 100 pg/mL

  • ULOQ: > 20,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Sample volume: 15 µL/test

Description:

Epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands. EGF R signaling regulates multiple biological functions including cell proliferation, differentiation, motility, and apoptosis. EGF R is over-expressed in a wide variety of tumors and is the target of several anti-cancer drugs. Soluble receptors consisting of the extracellular ligand binding domain are generated by alternate splicing in human and mouse. Diseases associated with EGFR include Inflammatory Skin and Bowel Disease and Giant Cell Glioblastoma.

References:

  1. Herbst RS (2004). "Review of epidermal growth factor receptor biology". International Journal of Radiation Oncology, Biology, Physics. 59 (2 Suppl): 21–6. doi:10.1016/j.ijrobp.2003.11.041. PMID 15142631.

  2. Jump up ^ Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI (August 2007). "ErbB receptors: from oncogenes to targeted cancer therapies". The Journal of Clinical Investigation. 117 (8): 2051–8. doi:10.1172/JCI32278. PMC 1934579. PMID 17671639.

  3. Jump up ^ Yarden Y, Schlessinger J (March 1987). "Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor". Biochemistry. 26 (5): 1443–51. doi:10.1021/bi00379a035. PMID 3494473.

  4. Jump up ^ Downward J, Parker P, Waterfield MD (1984). "Autophosphorylation sites on the epidermal growth factor receptor". Nature. 311 (5985): 483–5. doi:10.1038/311483a0. PMID 6090945.